Peerview Infectious Diseases Cme/cne/cpe Audio Podcast

Informações:

Synopsis

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episodes

  • Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Challenges in the Diagnosis and Treatment of Invasive Fungal Infections: A Visual Guide for Clinicians on the Front Lines of Patient Care

    11/01/2021 Duration: 58min

    Go online to PeerView.com/JZZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an infectious diseases specialist provides guidance on improving the diagnosis and treatment of invasive fungal infections. Upon completion of this activity, participants will be able to: Describe the epidemiology and risk factors for invasive fungal infections in patients who are immunocompromised and/or immunosuppressed, Promptly evaluate high-risk patients with signs or symptoms that are suggestive of systemic fungal infection to mitigate the impact of delayed recognition and initiation of antifungal therapy, Discuss available diagnostic tests and emerging technologies to ensure early detection of invasive fungal infections, Outline the role of antifungal susceptibility testing in guiding therapeutic decision-making for invasive fungal infections, Optimize the efficacy, tolerability, and cost-effectiveness of antifungal therapy in individual patients with in

  • Jesse Papenburg, MD, MSc, FRCPC - Reducing the Burden of Influenza on Children: An Exploration of Novel and Emerging Antiviral Therapy

    06/11/2020 Duration: 44min

    Go online to PeerView.com/GFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of antiviral therapy in pediatric patients with influenza. Upon completion of this activity, participants will be able to: Discuss the underutilization of antiviral treatment for both adult and pediatric patients in the management of influenza, despite recommendations from practice guidelines, Describe the benefits and shortcomings associated with the use of diagnostic assays in detecting influenza in terms of sensitivity, specificity, and convenience, Assess currently available and novel/emerging antiviral therapies for the treatment of pediatric patients with influenza, based on the latest clinical data concerning efficacy, safety, tolerability, dosing, and routes of administration, Select antiviral treatment for pediatric patients with influenza, based on the latest clinical evidence and current guideline recommendati

  • Paul E. Sax, MD - Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care

    03/09/2020 Duration: 40min

    Go online to PeerView.com/QDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses guidance for healthcare professionals involved in the treatment of patients with COVID-19. Upon completion of this activity, participants will be able to: Describe the epidemiology and virology of coronavirus disease 2019 (COVID-19), Evaluate patients with suspected COVID-19 infection in accordance with current guidance from the Centers for Disease Control and Prevention (CDC), recognizing that recommendations may be adapted by state and local health departments to respond to rapidly changing local circumstances, Assess the efficacy, safety, and appropriate clinical utilization of current and emerging COVID-19 management and prevention strategies, Employ evidence-based protocols to provide appropriate care for patients with suspected or confirmed COVID-19.

  • Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    24/04/2020 Duration: 47min

    Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

  • Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

    22/04/2020 Duration: 46min

    Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribav

  • Stacey B. Trooskin, MD, PhD - HCV 20 x 20: A Screening Initiative to Increase Hepatitis C Testing, Diagnosis, and Linkage to Care in High-Risk Populations

    22/01/2020 Duration: 21min

    Go online to PeerView.com/QWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious disease discusses strategies for increasing testing, diagnosis, and linkage to care in individuals who are at high risk for hepatitis C infection. Upon completion of this activity, participants should be better able to: Identify persons for whom HCV testing is recommended, Utilize appropriate diagnostic testing strategies for HCV, Incorporate national guidelines for HCV testing and diagnosis into routine clinical practice, Develop effective follow-up, counseling, and quality care strategies for patients with a confirmed diagnosis of HCV

  • Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    17/01/2020 Duration: 01h30min

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction wit

  • Donna E. Sweet, MD, AAHIVS, MACP - Creating an HIV Prevention–Certified Provider Workforce: A Training and Certificate Program Designed to Improve the Competencies of Providers to Deliver Comprehensive HIV Prevention

    25/11/2019 Duration: 38min

    Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numero

  • Joshua D. Lee, MD, MSc - Caring for the Patient With Opioid Use Disorder in an Outpatient Setting: Overcoming the Barriers to Medication-Assisted Treatment

    15/11/2019 Duration: 40min

    Go online to PeerView.com/XXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in addiction medicine discusses opioid use disorder in the outpatient setting and overcoming the various barriers to patients receiving medication. Upon completion of this activity, participants should be better able to: Identify barriers to the implementation of medication-assisted treatment (MAT) for patients with opioid use disorder (OUD), Discuss the efficacy of treatment programs that include MAT for the management of OUD, Employ strategies to effectively and safely integrate MAT into the management of patients with OUD, to reduce opioid misuse and improve treatment retention, particularly in the outpatient setting

  • Andrew F. Shorr, MD, MPH, MBA, FACP, FCCP - Improving the Diagnosis, Treatment, and Outcomes of Patients With HAP and VAP: A Critical Look at Current Guidelines and New Treatment Options

    25/10/2019 Duration: 36min

    Go online to PeerView.com/GBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonary and critical care medicine discusses the microbiology, diagnosis, and treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Upon completion of this activity, participants will be able to: List the pathogens commonly implicated in causing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), Identify risk factors for multidrug-resistant HAP and VAP, Employ an evidence-based approach to readily diagnose HAP and VAP in the critical care setting, Select empiric therapy for HAP and VAP based on the local distribution of pathogens and their antimicrobial susceptibilities, as well as individual patients’ risk factors for multidrug resistance and prior microbiology data, Summarize key features and critical differences between novel antibiotics for the treatment of HAP and VAP, Optimize an

  • Doreen Addrizzo-Harris, MD - Advances in the Management of Nontuberculous Mycobacterial Lung Disease (NTM-LD): Expert Insights From Dallas

    08/07/2019 Duration: 28min

    Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

  • Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care

    15/05/2019 Duration: 34min

    Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regim

  • David E. Griffith, MD - Exploring the Path Forward in Nontuberculous Mycobacterial Lung Disease: A MasterClass on Risk Factors, Diagnosis, and Treatment

    24/04/2019 Duration: 51min

    Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, hea

  • Roy F. Chemaly, MD, MPH, FIDSA, FACP - Managing CMV in the New Era of Antiviral Therapy: Practical Considerations in the HCT Setting

    03/04/2019 Duration: 49min

    Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case s

  • Richard S. Finn, MD - Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

    08/03/2019 Duration: 01h14min

    Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

  • Gregory Piazza, MD, MS - Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

    22/02/2019 Duration: 33min

    Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

  • Mark S. Sulkowski, MD - Addressing the Evolving Opioid and HCV Epidemics Through Community Engagement and Education

    14/01/2019 Duration: 01h23min

    Addressing the Evolving Opioid and HCV Epidemics Through Community Engagement and Education

  • Jorge A. Marrero, MD, MS - Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes

    11/01/2019 Duration: 01h32min

    Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes

  • Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Barriers to Optimal Diagnosis and Treatment of Invasive Fungal Infections: Practical Guidance for the Hospital-Based Healthcare Provider

    10/09/2018 Duration: 26min

    Overcoming Barriers to Optimal Diagnosis and Treatment of Invasive Fungal Infections: Practical Guidance for the Hospital-Based Healthcare Provider